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ABSTRACT
Alternative splicing enables expression of function-
ally diverse protein isoforms. The structural and
functional complexity of zinc-finger transcription
factor ZBP-89 suggests that it may be among the
class of alternatively spliced genes. We identified a
humanZBP-89spliceisoform(ZBP-89
DN),whichlacks
amino terminal residues 1–127 of the full-length pro-
tein (ZBP-89
FL). ZBP-89
DN mRNA was co-expressed
with its ZBP-89
FL cognate in gastrointestinal cell
lines and tissues. Similarly, ZBP-89
DN protein was
expressed.Todefineitsfunctioninvivo,wegenerated
ZBP-89
DN knock-in mice by targeting exon 4 that
encodes the amino terminus. Homozygous ZBP-
89
DN mice, expressing only ZBP-89
DN protein, experi-
enced growth delay, reduced viability and increased
susceptibility to dextran sodium sulfate colitis.
We conclude that ZBP-89
DN antagonizes ZBP-89
FL
function and that over-expression of the truncated
isoform disrupts gastrointestinal homeostasis.
INTRODUCTION
Alternative pre-mRNA splicing and multiple promoter usage
are common mechanisms for increasing genetic complexity in
humans (1) and mice (2). Genome-wide analyses indicate that
the majority of human genes express alternative splice iso-
forms (3) and some variants contribute to neoplasia or other
disease processes (4,5).For example, truncated isoforms of the
p53 gene family, including p63 (6) and p73 (7–9), oppose the
tumor suppressor activity of their full-length cognates and are
over-expressed in tumors.
ZBP-89 (ZNF148; Zfp148; BFCOL1), a Kru ¨ppel-type zinc-
ﬁnger protein (10), is both structurally (11) and functionally
complex (12–14). It regulates diverse biological functions
through direct promoter binding (10,14) and through multiple
protein–protein interactions. It interacts directly with the
tumor suppressor p53 through its zinc-ﬁnger domain (13)
and indirectly with the histone acetyltransferase and transcrip-
tional co-activator p300 through its amino terminus (12).
ZBP-89 induces cell growth arrest through a p53-dependent
mechanism (13) and apoptosis through a p53-independent
mechanism (12). Mice haploinsufﬁcient for ZBP-89
(Zfp148) are sterile owing to aberrant spermatogenesis (15).
In addition, embryonic stem cells harboring a single ZBP-89
allele fail to exhibit p53 phosphorylation at Ser 15 (15).
ZBP-89 forms a complex with p300 during butyrate induc-
tion of p21
waf1 in human colorectal cell lines (12). The amino
terminus of ZBP-89 contains an acidic domain that is required
for p300-mediated induction, since an expression construct
lacking this domain (D amino acids 1–113) loses its ability
to enhance butyrate induction of p21
waf1 (12). The acidic
domain of ZBP-89 is contained entirely within exon 4 of
the human and mouse genes (11). Given the heterogeneous
ZBP-89 mRNA expression pattern (10), the functional impor-
tance of the p300 interaction domain, and the fact that
the ZBP-89 null mouse is likely an embryonic lethal (15),
we generated a mouse homozygous for the ZBP-89
DN
isoform. Homozygous DNter mice experienced growth
delay, reduced viability and increased susceptibility to Dex-
tran sodium sulfate (DSS) induced colitis, suggesting that
over-expression of the DNter isoform disrupts normal
gastrointestinal homeostasis.
MATERIALS AND METHODS
Database deposition
National Center for Biotechnology Information (NCBI) refer-
ence sequences for ZBP-89 genomic loci are Homo sapiens
chromosome 3 locus NC_000003 and BAC RP11-775J23
(AC108688); Mus musculus chromosome 16 contig
NT_039624 and Pan troglodytes chromosome 3 genomic
locus NW_104931. The human ZBP-89
DN mRNA and exon
4B genomic sequences reported here are found in GenBank as
entries DQ090088 and DQ090089, respectively. The P.troglo-
dytes genomic sequence homologous to human exon 4B is
deposited in Genbank DQ144540.
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doi:10.1093/nar/gkl022Organization of the human (ZNF148), chimp
and mouse (Zfp148) ZBP-89 loci
A human genomic clone contig encompassing the ZBP-89
locus was previously described (14). Bacterial artiﬁcial chro-
mosome (BAC) clones were used as templates to sequence
intron/exon boundaries spanning the ZNF148 locus. Exon 4B
was identiﬁed by gene prediction sequence analysis (16,17).
Similarly, a BAC and bacteriophage lambda clone contig
spanning the mouse Zfp148 locus was assembled and sequ-
enced to determine the genomic organization of the Zfp148
locus. Primers Ptr-4B-F: 50-TTCACCTCCCTGTCCTGTTC-30
and Ptr-4B-R: 50-TATCTGTCCCGTTTGCCTG-30 were used
to amplify and sequence chimp (P.troglodytes)g e n o m i cD N A
containing exon 4B, after BLAST analysis (18) had revealed a
sequencegapinthisregion.ChimpgenomicDNAwasobtained
from the Integrated Primate Biomaterials and Information
Resource through the Coriell Institute for Medical Research
(Camden, NJ).
RT–PCR analysis
Total cellular RNA was isolated from cultured cells using
TRIzol reagent (Invitrogen, Carlsbad, CA). Archived whole
cell RNA samples from paired colon cancer and normal
mucosal samples were also analyzed. Two-step RT–PCR
was performed usingSuperScript III RT (Invitrogen), however
reverse transcription was performed at 55 C in order to obtain
adequate yields of human exon 4B-containing cDNA.
RT reactions were primed with random nonamers. Human
primer sequences (50 to 30) were 4A-F: ATGAACATTGAC-
GACAAACTGGAAG; 5-R: TTCCATATGATATTTTTG-
TATGAAT; 4B-F: TAGGGATGGTCAGCACTG; 6-R:
GTTCTTTTGTGCCTTTCC. Mouse primer sequences
(50 to 30) included Ex2-F: GCGGATAGAAGAGAAG-
AATCAGTGG; Ex4-F: CATTGACGACAAACTGGAAGG;
Ex4-R: ACTTCGATCTTGAAGTACTGACTC; Ex5-R:
CAGGAGAGCGTTGTTTCCG; Ex3/5fusion-F: CAGCC-
TCAGATAAGTGTA and Ex9-R: TTGTGGCATCTGGT-
GAAG. RT–PCR products were puriﬁed and subjected to
DNA sequence analysis (University of Michigan DNA
Sequencing Core).
50-RACE of human exon 4B
The 50 end of the exon 4B variant was identiﬁed using the
GeneRacer
TM system (Invitrogen, Carlsbad, CA), gene spe-
ciﬁc primer (50 to 30) 4B211-Rev: CAGTGCTGACCATCCC-
TATC CTACTTG and 2 mg of Jurkat whole cell RNA. Nested
PCR products, generated with adaptor primers included with
the GeneRacerTM system, were cloned using the TOPO-TA
system (Invitrogen, Carlsbad, CA), and sequenced.
Targeting vector
We constructed vector pDEx-4 to replace ZBP-89 exon 4 with
a PGK-Neo cassette by homologous recombination. High
ﬁdelity long-range PCR was used to amplify targeting arms
from mouse BAC clone pBmZBP-89, using primers (50 to 30):
(Kpn)Int3-F, GATAGGTACCGCATTGGATGGCACAAG-
TGACTGAGAGG with (Xho)Int3-R, CTCGAGCCCGGGC-
TTAAGTATAACTGCCTAGAAAG for the left arm and
(Apa)Int4-F, CTCGAGGGGCCCGTAAGTACTAAACTA-
GAAATG with (Apa)Int4-R, CTCGAGGGGCCCAAGAGC-
CTTGCTGACTCATAG for the right arm. The left targeting
arm, encompassing exon 3 and intron 3, was 8 kb in length.
Therighttargetingarmconsistedofthe proximal 2kbofintron
4. The neomycin cassette, including a transcriptional stop
signal, was isolated from pPNT (19), generously provided
by Dr Richard Mulligan.
Generation of targeted ES cells and DNter mice
Electroporation of embryonic stem (ES) cells with the pDEx-4
targeting vector and microinjection of blastocysts with tar-
geted ES cells were performed by the University of Michigan
Transgenic Animal Model Core (www.med.umich.edu/tamc).
Genomic PCR was utilized to genotype targeted 129 Sv/J ES
clones, chimeric founders, and progeny resulting after germ-
line transmission. Primer sequences (50 to 30) were Int3-F1,
GGAGTATTCTCTGTCCGTT ATG; Int4-326R, GCAAGA-
ACTACACAGAGAAACCAC and R506Neo, TGAGGAA
GAGGAGAACAGCG.
Two-dimensional western blot analysis
Whole cell protein extracts were prepared from mouse spleen
using T-PER tissue protein extraction reagent (Pierce,
Rockford, IL), supplemented with Complete Mini protease
inhibitors (Roche, Indianapolis, IN) according the manufac-
turers’ recommendations. Whole cell protein extracts
from human Jurkat cells were similarly prepared using
M-PER mammalian protein extraction reagent (Pierce,
Rockford, IL). Isoelectric focusing (IEF) was performed
with 7 cm ZOOM  Strip ph3-10L (linear) immobilized
pH gradient gels (Invitrogen, Carlsbad, CA), as recommended
by the manufacturer. The focused proteins were then separated
on NuPAGE  4-12% acrylamide gels (Invitrogen).
Electroblot transfer to PVDF membrane and immuno-
blot procedures with ZBP-89 antiserum are as previously
described (10,12).
Dextran sodium sulfate colitis
DSS colitis was induced in 6–9 month old ZBP-89
DN and
littermate control mice by the addition of 4% DSS to drinking
water for a period of 5 days (20). Treated mice were returned
to normal drinking water for 2 days prior to necropsy for
histopathological scoring. Hematoxylin and eosin (H&E)
stained colon sections were prepared by the Swiss roll method
(21) and were scored for colitis index by a modiﬁcation of a
previously described method (22). Brieﬂy, crypt damage was
scored from 0 to 3 as none, basal only, moderate damage and
complete erosion, respectively. Inﬂammation was scored from
0 to 3 as none, minor, moderate and severe leukocyte inﬁl-
tration. Submucosal edema was scored from 0 to 3 as none,
minor, moderate and severe, respectively. Similarly, hemor-
rhage was scored from 0 to 3 as none, minor, moderate and
severe. Each parameter was multiplied by an extent factor (1–
3), <10%, up to 25%, 25 to 50% and >50%, respectively.
Samples with transmural involvement received an additional
four points. Therefore, the maximum possible colitis index
score was 40. Animals that died during treatment because
of colitis injury were also given the maximum score. Individu-
als scoring the samples were blinded to the genotype.
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Thefollowingcelllines were obtainedfromATCC(Manassas,
VA) and maintained on the recommended growth media:
Human gastric epithelial cells Kato III and MKN45; human
colon cancer cells Colo 320DM, CaCo-2 and HCT116; and
human Jurkat leukemia cells. Cells were cultured in a humidi-
ﬁed atmosphere of 5% CO2 and 95% air at 37 C. All culture
media were supplemented with penicillin G (100 U/ml) and
streptomycin (100 mg/ml).
RESULTS
Identification of human ZBP-89
DN isoform
To determine if isoforms of ZBP-89 exist, we screened the
human ZNF148 genomic locus in silico (16,17). After local-
izing candidate alternative exon 4B within 4 kb upstream of
exon 5 (Figure 1A), we used RT–PCR analysis to show that
exon 4B is expressed (Figure 1B). Exon 4B mRNA (DN) was
co-expressed with exon 4A-containing message (FL) in colon
cancer cells (ColoDM2, CaCo2, HCT116), and in primary
tissue from normal colon and colon adenocarcinoma. Both
forms also were abundantly expressed in Jurkat cells (data
not shown). This suggested that at least two forms of
ZBP-89 exist.
To better understand the function of the isoform, exon 4B-
containing cDNA was sequenced. In addition to exon 4B, the
variant mRNA included exons 5 and 6 (Figure 2A), as well as
exons 7–9 (not shown). In contrast, RT–PCR with forward
primers from exons 1-4A failed to generate productswith exon
4Bantisenseprimers,suggestingthat anindependentpromoter
regulates exon 4B expression. This was conﬁrmed by 50-rapid
ampliﬁcation of cDNA ends (RACE), which showed that tran-
scription was initiated immediately upstream of exon 4B. The
cDNA sequence showed that exon 4B was spliced to exon 5
resulting in an alternative reading frame relative to the cDNA
encoded by exon 4A (Figure 2A). Exon 4B was 329 nt in
length and composed of untranslated sequences when fused
to exon 5. These data predicted that alternative promoter usage
upstream of exon 4B resulted in the expression of an amino-
terminally truncated ZBP-89 isoform, ZBP-89
DN, with an
alternative initiation codon corresponding to M128 of full-
length mRNA (Figure 2B). This isoform lacks the acidic
domain and p300-interaction region (12) found in full-
length(ZBP-89
FL)protein(10).Identicalresultswereobtained
with cDNA derived from esophagus, stomach, colon and
Jurkat T-cells, suggesting that the exon 4B alternative
promoter mechanism is common.
Detection of human ZBP-89
DN protein
We found that the electrophoretic mobility of ZBP-89
DN
protein,despiteitsshorter length, overlappedwith themobility
of its ZBP-89
FL cognate (Figure 2C). Both forms, isolated
from Jurkat cells, migrated at 100 kDa on a 4–20% gradient
gel. Similar SDS–PAGE anomalies have been reported with
other proteins, including CTCF (23) and XPA (24). An alter-
native approachtoseparatethe proteinisoformswas suggested
by comparing their predicted (25) isoelectric points (pI). Loss
of the acidic domain in ZBP-89
DN protein predicted a pI of 7.8,
compared to 6.0 for ZBP-89
FL. This difference could be
Figure 1. Identification of a novel exon within the human ZBP-89 (ZNF148) locus. (A) The human ZBP-89 (ZNF148) locus spans 142 kb (upper panel) and
encompassesthreeuntranslated(1–3)andsixcoding(4–9)exons.Apotentialalternativeexon4B(shadedbox)wasidentifiedataposition4.2kbupstreamofexon5.
Arrows indicate the locations of forward (F) and reverse (R) RT–PCR primers used for expression analysis of FL ZBP-89 and the exon 4B variant. Selected intron
sizes (kb) are indicated. (B) RT–PCR analysis of full-length (FL) and variant (DN) ZBP-89 mRNA expression, using actin (Ac) as control. The cDNAs were
generated with cultured cell lines using primers 4A-F/5-R (726 bp product); primers 4B-F/6-R (432 bp product) and (Ac), Actin control primers (400 bp product).
Whole cell RNA was isolated from ColoDM2, CaCo 2, and HCT116 human colon cell lines as well as paired normal colon and colon adenocarcinoma tissue.
Full-length message is expressed from promoter 1 (Pro 1) and variant (DN) ZBP-89 mRNA is expressed from promoter 2 (Pro 2), as described in Figure 2.
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followed by western blot analysis (Figure 2C). ZBP-89
antiserum detected two protein species, with apparent
electrophoretic mobilities of 100 kDa, but with a pI difference
of  1.5, conﬁrming that the more basic form is ZBP-89
DN.
ZBP-89
DN alternative promoter mechanism
is restricted to hominids
Although the human (ZNF148) and mouse (Zfp148) ZBP-89
loci share many features of genomic organization (11), exon
4B is absent in mice and most other mammals (data not
shown). In contrast, we identiﬁed a 133 bp segment of
chimpanzee (P.troglodytes) chromosome 3 sequence with
striking DNA sequence homology to human exon 4B, but
there was a gap in the existing online genomic sequence.
Sequencing across the gap after genomic DNA ampliﬁcation,
we found that the chimp shares 99% DNA sequence identity
to the 329 bp human exon 4B. This suggested that the
ZBP-89
DN alternative promoter mechanism is restricted to
hominids.
Generating a mouse model of ZBP-89
DN expression
Since mice lack exon 4B, and therefore do not express a
ZBP-89
DN isoform, we targeted the mouse exon 4 domain
by homologous recombination (Figure 3A). The left targeting
arm contained exon 3 and intron 3, and the right targeting arm
contained 1.8 kb of the 50 margin of intron 4. Homologous
recombination occurred in 4 of 1200 ES clones identiﬁed by
PCR (Figure 3B). Of the four homologous recombinants, three
demonstrated stable karyotypes and were therefore injected
into blastocysts. Germline transmission of the exon 4-targeted
locus resulted in two founder lines, 4E10 and 8C6, while a
third founder, 9C6, failed to transmit the recombinant locus.
Germline transmission was obtained ﬁrst in the 4E10 lineage.
Near-Mendelian ratios were observed at the age of weaning (3
weeks) in offspring of heterozygous intercrosses (Figure 3C).
The data suggested that  20% of Dexon4 homozygous
embryos die in utero or perinatally, however the difference
between predicted and observed DExon4/DExon4 yields was
not statistically signiﬁcant (c
2-square analysis; P > 0.05). A
similar pattern was observed in the 8C6 lineage. These results
also suggest that the mutant locus was at least partially
functional, since heterozygosity for a null ZBP-89 (Zfp148)
allele results in failed germ cell development and therefore is
not transmitted (15).
Alternative splicing of exon 3 to exon 5
in recombinant mice
To determine the effect of exon 4 deletion on ZBP-89 expres-
sion, we analyzed cDNA derived from normal, heterozygous
Figure 2. Variant ZBP-89 transcript encodes a truncated protein, ZBP-89
DN.( A) The 50 end of exon 4B-variant cDNA, determined by 50-RACE, is shown.
Underlined italics, exon 4B-encoded; lower case italics, exon 5 untranslated (frameshift relative to ZBP-89
FL cDNA); upper case italics, exon 5 coding sequence
commencing at M128 relative to FL protein; upper case underlined, beginning of exon 6-encoded. The remainder of the cDNA and amino acid sequences are
identicaltothecorrespondingsegmentsofFLcDNAandprotein.(B)ComparisonofFL(upper)andDN(lower)proteinisoforms.TheaminoterminusofZBP-89
FL
includes an acidic and p300-interaction domain (PID), which is absent in ZBP-89
DN. The ZBP-89
DN isoform retains the DNA binding and C-terminal domains.
(C) 2D western blot analysis of Jurkat whole cell protein extract. ZBP-89
FL (solid triangle) and ZBP-89
DN (open triangle) peptides share an electrohoretic mobility
of  100 kDa and are separated on the basis of their distinct isoelectric points (pI). The acidic end of the focusing gel is at the left.
Nucleic Acids Research, 2006, Vol. 34, No. 5 1345and exon 4-targeted animals (Figure 4A). Whereas exon
4 sequences were absent from recombinant mRNA, both
upstream and downstream exons were expressed. RT–PCR
with primers spanning exon 4 generated a 690 bp cDNA
from wild type and a 339 bp cDNA from mutant alleles.
The size difference between WT and targeted cDNA was
351 bp, the size of exon 4. This suggested that exon 3 was
spliced directly to exon 5, excluding the intervening Neo
cassette, and this was conﬁrmed by DNA sequencing
(Figure 4B). Deletion of exon 4 removed the initiation
codon found in FL message and also resulted in an alternative
reading frame. Gene feature sequence analysis (16,17)
predicted that the alternative initiation codon corresponded
to M128 of the FL protein (Figure 4B), analogous to the
human ZBP-89
DN variant (Figure 2B).
Mouse ZBP-89
DN protein expression
2D western blot analysis (Figure 4C) showed that ZBP-89
FL
and ZBP-89
DN proteins are expressed in an allele-dependent
manner. The two forms have similar electrophoretic mobilities
of 100 kDa, but are readily separated by their pI differences,
similar to the human isoforms (Figure 2C). As mentioned
above, similar electrophoretic anomalies have been observed
with other protein isoforms (23,24). The immunoblot data also
suggest that the DN protein isoform may be present at higher
levels than the FL form in spleen tissue, however mRNA
levels appear comparable, suggesting a possible difference
in protein stability. Collectively, the mRNA and protein
expression data conﬁrmed that we knocked the ZBP-89
DN
variant into the mouse genome. Thus, the mouse model offers
the advantage of assessing the biological effect of ZBP-89
DN
expression exclusively.
ZBP-89
DN/DN mice experience growth delay
and reduced viability
At weaning, by age 3 weeks, male ZBP-89
DN/DN mice weighed
an average of 5.9 ± 0.5 g (Figure 5A), 34% smaller than ZBP-
89
FL/FL (12.1 ± 0.7 g) and 49% smaller than ZBP-89
FL/DN
heterozygous littermates (15.1 ± 0.8 g). From ages 4–8
weeks, the size differential between ZBP-89
DN/DN and control
micewasdiminished.Asimilareffectwasobservedwithfemale
mice (data not shown). As shown above (Figure 3C),
ZBP-89
DN/DN mice experienced 20% perinatal mortality as
determined by genotype ratios at weaning. Reduced viability
persisted and became statistically signiﬁcant (Figure 5B), with
50% mortality at 48 weeks and 69% mortality by 104 weeks.
The 2 year survival ratios were 20:20 ZBP-89
FL/FL, 39:40
ZBP-89
FL/DN and 5:16 ZBP-89
DN/DN mice. Histopathological
organ and tissue surveys revealed no obvious abnormalities in
ZBP-89
DN/DN mice, with the possible exception of the colon,
where we noted a trend toward slightly increased lymphocytic
inﬁltrates (data not shown). Semi-quantitative RT–PCR
analysis of colon mRNA levels (Figure 5C), suggested that
FL and DN forms were expressed in an allele-dependent
manner. Collectively, these data demonstrated that balanced
expression of ZBP-89
FL and ZBP-89
DN isoforms, as observed
in heterozygous mice, supports normal growth and viability.
In contrast, exclusive expression of the ZBP-89
DN isoform
in transgenic mice resulted in growth delay and reduced
viability.
ZBP-89
DN confers DSS colitis susceptibility
We previously showed that the amino terminal region of ZBP-
89 (amino acids 1–111) is required to potentiate butyrate
Figure 3. TargetingZBP-89exon4inmice.(A) Replacementofexon4witha Neomycinresistancecassette(NEO)byhomologousrecombination inEScells.Top
panel: bracket shows location of features encoded by exon 4, including initiation codon, acidic domain (black rectangle) and p300 interaction domain. Open boxes,
basic domains; hatchedboxes,zinc-fingers;stippledregion,untranslated.Middle panel;Zfp148genomic locus.Intronsizes(kb) are shown.Lowerpanel;targeting
strategy. (B) Tail biopsy DNA genotyping. WT (Int 3 F/Int 4 R) and Dexon4 (Int 3 F/Neo R) amplimers. (C) Near-Mendelian inheritance of DExon-4 alleles. The
differences between predicted and observed values were not significant.
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DN.(A)RT–PCRanalysiswasusedtodeterminethevariantmRNAstructureinrecombinantmice.Spleenwhole-cell
RNA was reverse-transcribed and amplified with primers within the indicated exons. RT–PCR of another ubiquitously expressed zinc-finger transcription factor,
Sp1, was used for comparison and showed that the RNA samples were of uniform quality. Control experiments showed that PCR products were RT-dependent
(data not shown), indicating that they were indeed derived from mRNA rather than possibly resulting from amplification of ZBP-89 related processed pseudogene
sequences,suchasYBERF1(32).(B)DNAsequencingofrecombinantcDNAshowedthatdeletionofexon4resultedindirectsplicingofexon3toexon5,excluding
the Neo cassette. The resulting reading frameshift predicts an alternative initiation codon corresponding to M128 of FL protein, similar to the naturally occurring
human ZBP-89
DN variant. (C) 2D immunoblot analysis of whole-cell spleen protein extracts from FL/FL, FL/DN and DN/DN mice, using conditions identical to
those used for analysis of human samples (Figure 2C).
Figure 5. Growthdelayand decreased survivalin DNtermice.(A) GrowthcurveformaleZBP-89
FL/FL(graydashedline,n ¼ 20),ZBP-89
FL/DN (blackdotted line,
n ¼ 36), and ZBP-89
DN/DN (black solid line, n ¼ 16) offspring. A similar pattern was seen with female mice (not shown). ** P < 0.01; * P < 0.05. A trend toward
lower body weights in ZBP-89
DN/DN persisted after 12 weeks, but was no longer statistically significant (data not shown). (B) Kaplan–Meier analysis of survival
interval to the onset of morbidity or death. (C) Semi-quantitative RT–PCR analysis of ZBP-89
FL and ZBP-89
DN mRNA levels in the colon.
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waf1, suggesting that the amino terminal
region mediates the butyrate-dependent anti-proliferative
activities of ZBP-89 in the mammalian gastrointestinal tract
(12). Butyrate suppresses colonic inﬂammation when induced
by DSS (26). Since DSS accentuates a tendency to develop
colitis, we challenged ZBP-89
DN/DN mice acutely with 4%
DSS for 5 days, as previously described (20). Histopathogical
analysis (hematoxylin and eosin stained sections) demon-
strated the presence of severe colitis that correlated with a
ZBP-89
DN gene dosage effect (Figure 6A–C). ZBP-89
FL/FL
mice (Figure 6A) had localized areas of lymphocytic inﬁltra-
tion and minimal submucosal edema. ZBP-89
FL/DN mice
(Figure 6B) exhibited more extensive inﬁltration, with dis-
placed normal crypt architecture in addition to submucosal
edema. ZBP-89
DN/DN mice (Figure 6C) had areas with com-
plete erosion of crypt architecture, grossly visible hemorrhage
and extensive submucosal edema. The ZBP-89
DN gene dosage
effect also correlated with the duration of gastrointestinal
bleeding (Figure 6D). Moreover, only ZBP-89
DN/DN mice
died during DSS treatment, with 50% mortality by the
conclusion of the 7 day regimen (Figure 6E). Composite
colitis scoring similarly paralleled the ZBP-89
DN gene dosage
(Figure 6F). These data suggest that increased expression
of ZBP-89
DN is associated with increased susceptibility
to colitis.
DISCUSSION
Through structural and functional analyses, we identiﬁed a
human-speciﬁc ZBP-89 splice isoform, ZBP-89
DN, which
was generated by alternative promoter usage upstream of an
alternative exon 4B. As a consequence, ZBP-89
DN protein
lacks a transcriptional domain (12) found in its full-length
ZBP-89 cognate. This is the ﬁrst characterization of a ZBP-
89 isoform and is consistent with previous observations that
gene complexity is lower in mice than in humans. As many as
59% of human genes are alternatively spliced (27), while the
highest estimate to date for the mouse is 33% (28). Compara-
tive genomic analysis suggested that the ZBP-89
DN splicing
mechanism has been conserved between humans and chimps,
indicating that this speciﬁc mechanism of regulating ZBP-89
function is restricted to hominids.
Alternative mRNA expression increases genetic diversity
through regulatory mechanisms that also are implicated in
cancer (1,3–5,29) and other disease processes (30,31). The
human ZBP-89
DN variant described here renders the colonic
mucosa more susceptible to injury. Our previous studies
showed that the N-terminal domain is required for ZBP-89
to mediate butyrate-dependent activation of p21
waf1 by coop-
erating with p300 (12). This result demonstrated that the N
terminal domain is functionally important in vitro. Generating
Figure 6. IncreasedsusceptibilitytoDSScolitisinZBP-89
DNmice.(A–C)RepresentativeH&Estainsofnormal(A),heterozygous(B)andZBP-89
DN/DN(C)mice.
Inf ¼ infiltrating lymphocytes; SE ¼ submucosal edema; TM ¼ transmural inflammation. (D) DNter expression accelerates onset of gastrointestinal bleeding,
measuredbyfecaloccultbloodscreening.(E)MortalityduringDSStreatment:50%ofZBP-89
DN/ZBP-89
DNmicedieduring4%DSStreatment;allZBP-89
FL/ZBP-
89
FLand ZBP-89
FL/ZBP-89
DN micesurvived (six in each group).(F) Colitis indexscoringof DSS-treatedmice, as described in Materials and Methods; sixmice in
each genotype cohort.
1348 Nucleic Acids Research, 2006, Vol. 34, No. 5a mouse model in which only the truncated form was
expressed revealed that loss of the p300-interacting domain
results in delayed growth and a shortened lifespan. Although
theoveralleffectonthe healthoftheorganismwasimpressive,
an initial survey of several organs did not reveal obvious
abnormalities, with the exception of the colon, which appeared
to exhibit slightly more inﬂammatory inﬁltrates than the wild
type mice. The propensity of the ZBP-89
DN expressing mice to
develop colitis was subsequently uncovered when the animals
were challenged with DSS. Therefore, we concluded from
these studies that expression of ZBP-89
FL tends to protect
against colitis. The gene dosage dependence of colitis suscep-
tibility further suggests that the ZBP-89
DN isoform functions
as a dominant negative antagonist of ZBP-89
FL. Similar
antagonistic interactions have been reported between FL
and DN isoforms within the p53 gene family, including
DNp63 (29) and DNp73 (7–9).
The ZBP-89
DN knock-in model reported here, along with an
earlier Zfp148+/  model (15), help to elaborate how individ-
ual protein domains mediate the in vivo functions of ZBP-89.
Mice heterozygous for a null ZBP-89 allele demonstrate com-
plete failure of male germ cell development and are defective
in p53-dependent embryogenesis (15). This ﬁnding suggests
that the ability of ZBP-89 to interact with p53 is exquisitely
sensitive to gene dosage. In contrast, homozygous ZBP-89DN
expression is compatible with embryonic and postnatal
survival, albeit at reduced levels. We previously showed
that the DNA-binding, zinc-ﬁnger region of ZBP-89 mediates
its interaction with p53 (13), and this domain is retained in the
ZBP-89
DN isoform. Therefore, the Nter domain, which
includes the p300 interaction domain, is dispensable for
p53-dependent embryonic development and postnatal
survival, but is essential for normal gastrointestinal function.
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